APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Oligonucleotide Therapy-based Drug

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global Oligonucleotide Therapy-based Drug Industry Growth and Trends Forecast to 2032

Report ID 174018600120 December 2025121 pages

Choose your research edition.

Industry ResearchOligonucleotide Therapy-based Drug Industry Research Report 2026143 pages · $2,950 USDIndustry Growth & TrendsGlobal Oligonucleotide Therapy-based Drug Industry Growth and Trends Forecast to 2032121 pages · $3,450 USDMarket StructureGlobal Oligonucleotide Therapy-based Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Oligonucleotide Therapy-based Drug Market Outlook and Growth Opportunities 2026203 pages · $4,250 USDMarket Analysis & ForecastGlobal Oligonucleotide Therapy-based Drug Market Analysis and Forecast 2026-2032208 pages · $4,950 USD

Market perspective

According to APO Research, the global Oligonucleotide Therapy-based Drug market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for Oligonucleotide Therapy-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for Oligonucleotide Therapy-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Oligonucleotide Therapy-based Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global companies in the Oligonucleotide Therapy-based Drug market include Sobi, Novartis, Pfizer, Biogen, Sylentis, Silence Therapeutics, Secarna, Sarepta Therapeutics and Regulus Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global Oligonucleotide Therapy-based Drug market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The Oligonucleotide Therapy-based Drug market size, estimates, and forecasts are presented in terms of revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global Oligonucleotide Therapy-based Drug market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to Oligonucleotide Therapy-based Drug.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading companies in the global Oligonucleotide Therapy-based Drug market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue and gross margin data by manufacturer for 2021-2026, enabling benchmarking of scale, profitability, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

Oligonucleotide Therapy-based Drug Market by Company

Sobi

Novartis

Pfizer

Biogen

Sylentis

Silence Therapeutics

Secarna

Sarepta Therapeutics

Regulus Therapeutics

ProQR

Nippon Shinyaku

Moderna Therapeutics

MiNA Therapeutics

Jazz Pharmaceuticals

Ionis Pharmaceuticals

Dicerna

CureVac

BioNTech

Arrowhead

Alnylam

Oligonucleotide Therapy-based Drug Segment by Type

mRNA

siRNA

Antisense Oligonucleotides (ASO)

Oligonucleotide Therapy-based Drug Segment by Application

hATTR

Neuromuscular Diseases

COVID-19

Other

Oligonucleotide Therapy-based Drug Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Oligonucleotide Therapy-based Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Oligonucleotide Therapy-based Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market

5. This report helps stakeholders to gain insights into which regions to target globally

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Oligonucleotide Therapy-based Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2021-2025, 2026-2031). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 3: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 4: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 5: Detailed analysis of Oligonucleotide Therapy-based Drug companies' competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, revenue by country.

Chapter 12: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Global Oligonucleotide Therapy-based Drug Market Size (US$ Million) Comparison by Region: 2021 VS 2025 VS 2032 Table 2. Global Oligonucleotide Therapy-based Drug Market Size by Region (2021-2026) & (US$ Million) Table 3. Global Oligonucleotide Therapy-based Drug Market Share by Region (2021-2026) Table 4. Global Oligonucleotide Therapy-based Drug Market Size by Region (2027-2032) & (US$ Million) Table 5. Global Oligonucleotide Therapy-based Drug Market Share by Region (2027-2032) Table 6. Global Oligonucleotide Therapy-based Drug Market Size by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 7. Global Oligonucleotide Therapy-based Drug Market Size by Type (2021-2026) & (US$ Million) Table 8. Global Oligonucleotide Therapy-based Drug Market Size Share by Type (2021-2026) Table 9. Global Oligonucleotide Therapy-based Drug Market Size Forecasted by Type (2027-2032) & (US$ Million) Table 10. Global Oligonucleotide Therapy-based Drug Market Size Share Forecasted by Type (2027-2032) Table 11. North America Oligonucleotide Therapy-based Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 12. North America Oligonucleotide Therapy-based Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 13. Europe Oligonucleotide Therapy-based Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 14. Europe Oligonucleotide Therapy-based Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 15. Asia-Pacific Oligonucleotide Therapy-based Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 16. Asia-Pacific Oligonucleotide Therapy-based Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 17. Latin America Oligonucleotide Therapy-based Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 18. Latin America Oligonucleotide Therapy-based Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 19. Middle East and Africa Oligonucleotide Therapy-based Drug Market Size Breakdown by Type (2021-2026) & (US$ Million) Table 20. Middle East and Africa Oligonucleotide Therapy-based Drug Market Size Breakdown by Type (2027-2032) & (US$ Million) Table 21. Global Oligonucleotide Therapy-based Drug Market Size by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 22. Global Oligonucleotide Therapy-based Drug Market Size by Application (2021-2026) & (US$ Million) Table 23. Global Oligonucleotide Therapy-based Drug Market Size Share by Application (2021-2026) Table 24. Global Oligonucleotide Therapy-based Drug Market Size Forecasted by Application (2027-2032) & (US$ Million) Table 25. Global Oligonucleotide Therapy-based Drug Market Size Share Forecasted by Application (2027-2032) Table 26. North America Oligonucleotide Therapy-based Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 27. North America Oligonucleotide Therapy-based Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 28. Europe Oligonucleotide Therapy-based Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 29. Europe Oligonucleotide Therapy-based Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 30. Asia-Pacific Oligonucleotide Therapy-based Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 31. Asia-Pacific Oligonucleotide Therapy-based Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 32. Latin America Oligonucleotide Therapy-based Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 33. Latin America Oligonucleotide Therapy-based Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 34. Middle East and Africa Oligonucleotide Therapy-based Drug Market Size Breakdown by Application (2021-2026) & (US$ Million) Table 35. Middle East and Africa Oligonucleotide Therapy-based Drug Market Size Breakdown by Application (2027-2032) & (US$ Million) Table 36. Oligonucleotide Therapy-based Drug Industry Trends Table 37. Oligonucleotide Therapy-based Drug Industry Drivers Table 38. Oligonucleotide Therapy-based Drug Industry Opportunities and Challenges Table 39. Oligonucleotide Therapy-based Drug Industry Restraints Table 40. Global Oligonucleotide Therapy-based Drug Revenue by Company (US$ Million) & (2021-2026) Table 41. Global Oligonucleotide Therapy-based Drug Revenue Market Share by Company (2021-2026) Table 42. Global Oligonucleotide Therapy-based Drug Industry Company Ranking, 2024 VS 2025 VS 2026 Table 43. Global Oligonucleotide Therapy-based Drug Key Company Headquarters & Area Served Table 44. Global Oligonucleotide Therapy-based Drug Company, Product Type & Application Table 45. Global Oligonucleotide Therapy-based Drug Company Commercialization Time Table 46. Global Company Market Concentration Ratio (CR5 and HHI) Table 47. Global Oligonucleotide Therapy-based Drug by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 48. Sobi Company Information Table 49. Sobi Business Overview Table 50. Sobi Oligonucleotide Therapy-based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 51. Sobi Oligonucleotide Therapy-based Drug Product Portfolio Table 52. Sobi Recent Development Table 53. Novartis Company Information Table 54. Novartis Business Overview Table 55. Novartis Oligonucleotide Therapy-based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 56. Novartis Oligonucleotide Therapy-based Drug Product Portfolio Table 57. Novartis Recent Development Table 58. Pfizer Company Information Table 59. Pfizer Business Overview Table 60. Pfizer Oligonucleotide Therapy-based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 61. Pfizer Oligonucleotide Therapy-based Drug Product Portfolio Table 62. Pfizer Recent Development Table 63. Biogen Company Information Table 64. Biogen Business Overview Table 65. Biogen Oligonucleotide Therapy-based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 66. Biogen Oligonucleotide Therapy-based Drug Product Portfolio Table 67. Biogen Recent Development Table 68. Sylentis Company Information Table 69. Sylentis Business Overview Table 70. Sylentis Oligonucleotide Therapy-based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 71. Sylentis Oligonucleotide Therapy-based Drug Product Portfolio Table 72. Sylentis Recent Development Table 73. Silence Therapeutics Company Information Table 74. Silence Therapeutics Business Overview Table 75. Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 76. Silence Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio Table 77. Silence Therapeutics Recent Development Table 78. Secarna Company Information Table 79. Secarna Business Overview Table 80. Secarna Oligonucleotide Therapy-based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 81. Secarna Oligonucleotide Therapy-based Drug Product Portfolio Table 82. Secarna Recent Development Table 83. Sarepta Therapeutics Company Information Table 84. Sarepta Therapeutics Business Overview Table 85. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 86. Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio Table 87. Sarepta Therapeutics Recent Development Table 88. Regulus Therapeutics Company Information Table 89. Regulus Therapeutics Business Overview Table 90. Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 91. Regulus Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio Table 92. Regulus Therapeutics Recent Development Table 93. ProQR Company Information Table 94. ProQR Business Overview Table 95. ProQR Oligonucleotide Therapy-based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 96. ProQR Oligonucleotide Therapy-based Drug Product Portfolio Table 97. ProQR Recent Development Table 98. Nippon Shinyaku Company Information Table 99. Nippon Shinyaku Business Overview Table 100. Nippon Shinyaku Oligonucleotide Therapy-based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 101. Nippon Shinyaku Oligonucleotide Therapy-based Drug Product Portfolio Table 102. Nippon Shinyaku Recent Development Table 103. Moderna Therapeutics Company Information Table 104. Moderna Therapeutics Business Overview Table 105. Moderna Therapeutics Oligonucleotide Therapy-based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 106. Moderna Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio Table 107. Moderna Therapeutics Recent Development Table 108. MiNA Therapeutics Company Information Table 109. MiNA Therapeutics Business Overview Table 110. MiNA Therapeutics Oligonucleotide Therapy-based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 111. MiNA Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio Table 112. MiNA Therapeutics Recent Development Table 113. Jazz Pharmaceuticals Company Information Table 114. Jazz Pharmaceuticals Business Overview Table 115. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 116. Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product Portfolio Table 117. Jazz Pharmaceuticals Recent Development Table 118. Ionis Pharmaceuticals Company Information Table 119. Ionis Pharmaceuticals Business Overview Table 120. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 121. Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product Portfolio Table 122. Ionis Pharmaceuticals Recent Development Table 123. Dicerna Company Information Table 124. Dicerna Business Overview Table 125. Dicerna Oligonucleotide Therapy-based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 126. Dicerna Oligonucleotide Therapy-based Drug Product Portfolio Table 127. Dicerna Recent Development Table 128. CureVac Company Information Table 129. CureVac Business Overview Table 130. CureVac Oligonucleotide Therapy-based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 131. CureVac Oligonucleotide Therapy-based Drug Product Portfolio Table 132. CureVac Recent Development Table 133. BioNTech Company Information Table 134. BioNTech Business Overview Table 135. BioNTech Oligonucleotide Therapy-based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 136. BioNTech Oligonucleotide Therapy-based Drug Product Portfolio Table 137. BioNTech Recent Development Table 138. Arrowhead Company Information Table 139. Arrowhead Business Overview Table 140. Arrowhead Oligonucleotide Therapy-based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 141. Arrowhead Oligonucleotide Therapy-based Drug Product Portfolio Table 142. Arrowhead Recent Development Table 143. Alnylam Company Information Table 144. Alnylam Business Overview Table 145. Alnylam Oligonucleotide Therapy-based Drug Revenue (US$ Million), Global Share (%) and Gross Margin (2021-2026) Table 146. Alnylam Oligonucleotide Therapy-based Drug Product Portfolio Table 147. Alnylam Recent Development Table 148. North America Oligonucleotide Therapy-based Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 149. North America Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026) & (US$ Million) Table 150. North America Oligonucleotide Therapy-based Drug Market Share by Country (2021-2026) Table 151. North America Oligonucleotide Therapy-based Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 152. North America Oligonucleotide Therapy-based Drug Market Share Forecast by Country (2027-2032) Table 153. Europe Oligonucleotide Therapy-based Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 154. Europe Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026) & (US$ Million) Table 155. Europe Oligonucleotide Therapy-based Drug Market Share by Country (2021-2026) Table 156. Europe Oligonucleotide Therapy-based Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 157. Europe Oligonucleotide Therapy-based Drug Market Share Forecast by Country (2027-2032) Table 158. Asia-Pacific Oligonucleotide Therapy-based Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 159. Asia-Pacific Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026) & (US$ Million) Table 160. Asia-Pacific Oligonucleotide Therapy-based Drug Market Share by Country (2021-2026) Table 161. Asia-Pacific Oligonucleotide Therapy-based Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 162. Asia-Pacific Oligonucleotide Therapy-based Drug Market Share Forecast by Country (2027-2032) Table 163. Latin America Oligonucleotide Therapy-based Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 164. Latin America Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026) & (US$ Million) Table 165. Latin America Oligonucleotide Therapy-based Drug Market Share by Country (2021-2026) Table 166. Latin America Oligonucleotide Therapy-based Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 167. Latin America Oligonucleotide Therapy-based Drug Market Share Forecast by Country (2027-2032) Table 168. Middle East & Africa Oligonucleotide Therapy-based Drug Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 169. Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026) & (US$ Million) Table 170. Middle East & Africa Oligonucleotide Therapy-based Drug Market Share by Country (2021-2026) Table 171. Middle East & Africa Oligonucleotide Therapy-based Drug Market Size Forecast by Country (2027-2032) & (US$ Million) Table 172. Middle East & Africa Oligonucleotide Therapy-based Drug Market Share Forecast by Country (2027-2032) Table 173. Research Programs/Design for This Report Table 174. Authors List of This Report Table 175. Secondary Sources List of Figures Figure 1.List of Figures Figure 2. Oligonucleotide Therapy-based Drug Product Image Figure 3. Global Oligonucleotide Therapy-based Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 4. Global Oligonucleotide Therapy-based Drug Market Size (2021-2032) & (US$ Million) Figure 5. Global Oligonucleotide Therapy-based Drug Market Share by Region: 2025 VS 2032 Figure 6. Global Oligonucleotide Therapy-based Drug Market Share by Region (2021-2032) Figure 7. North America Oligonucleotide Therapy-based Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 8. Europe Oligonucleotide Therapy-based Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 9. Asia-Pacific Oligonucleotide Therapy-based Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 10. Latin America Oligonucleotide Therapy-based Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 11. Middle East & Africa Oligonucleotide Therapy-based Drug Market Size Growth Rate (2021-2032) & (US$ Million) Figure 12. mRNA Image Figure 13. Global mRNA Market Size YoY Growth (2021-2032) & (US$ Million) Figure 14. siRNA Image Figure 15. Global siRNA Market Size YoY Growth (2021-2032) & (US$ Million) Figure 16. Antisense Oligonucleotides (ASO) Image Figure 17. Global Antisense Oligonucleotides (ASO) Market Size YoY Growth (2021-2032) & (US$ Million) Figure 18. Global Oligonucleotide Therapy-based Drug Market Size Overview by Type (2021-2032) & (US$ Million) Figure 19. Global Oligonucleotide Therapy-based Drug Market Share by Type 2025 VS 2032 Figure 20. North America Oligonucleotide Therapy-based Drug Market Size Share by Type (2021-2032) Figure 21. Europe Oligonucleotide Therapy-based Drug Market Size Share by Type (2021-2032) Figure 22. Asia-Pacific Oligonucleotide Therapy-based Drug Market Size Share by Type (2021-2032) Figure 23. Latin America Oligonucleotide Therapy-based Drug Market Size Share by Type (2021-2032) Figure 24. Middle East and Africa Oligonucleotide Therapy-based Drug Market Size Share by Type (2021-2032) Figure 25. hATTR Image Figure 26. Global hATTR Market Size YoY Growth (2021-2032) & (US$ Million) Figure 27. Neuromuscular Diseases Image Figure 28. Global Neuromuscular Diseases Market Size YoY Growth (2021-2032) & (US$ Million) Figure 29. COVID-19 Image Figure 30. Global COVID-19 Market Size YoY Growth (2021-2032) & (US$ Million) Figure 31. Other Image Figure 32. Global Other Market Size YoY Growth (2021-2032) & (US$ Million) Figure 33. Global Oligonucleotide Therapy-based Drug Market Size Overview by Application (2021-2032) & (US$ Million) Figure 34. Global Oligonucleotide Therapy-based Drug Market Share by Application 2025 VS 2032 Figure 35. North America Oligonucleotide Therapy-based Drug Market Size Share by Application (2021-2032) Figure 36. Europe Oligonucleotide Therapy-based Drug Market Size Share by Application (2021-2032) Figure 37. Asia-Pacific Oligonucleotide Therapy-based Drug Market Size Share by Application (2021-2032) Figure 38. Latin America Oligonucleotide Therapy-based Drug Market Size Share by Application (2021-2032) Figure 39. Middle East and Africa Oligonucleotide Therapy-based Drug Market Size Share by Application (2021-2032) Figure 40. Global Top 5 and 10 Oligonucleotide Therapy-based Drug Players Market Share by Revenue in 2025 Figure 41. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 42. North America Oligonucleotide Therapy-based Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 43. North America Oligonucleotide Therapy-based Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 44. North America Oligonucleotide Therapy-based Drug Market Share by Country (2021-2032) Figure 45. Europe Oligonucleotide Therapy-based Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 46. Europe Oligonucleotide Therapy-based Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe Oligonucleotide Therapy-based Drug Market Share by Country (2021-2032) Figure 48. Asia-Pacific Oligonucleotide Therapy-based Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 49. Asia-Pacific Oligonucleotide Therapy-based Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 50. Asia-Pacific Oligonucleotide Therapy-based Drug Market Share by Country (2021-2032) Figure 51. Latin America Oligonucleotide Therapy-based Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Latin America Oligonucleotide Therapy-based Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America Oligonucleotide Therapy-based Drug Market Share by Country (2021-2032) Figure 54. Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 55. Middle East & Africa Oligonucleotide Therapy-based Drug Market Share by Country: 2021 VS 2025 VS 2032 Figure 56. Middle East & Africa Oligonucleotide Therapy-based Drug Market Share by Country (2021-2032) Figure 57. Years Considered Figure 58. Research Process Figure 59. Key Executives Interviewed

Scope & coverage.

Types
  • mRNA
  • siRNA
  • Antisense Oligonucleotides (ASO)
Applications
  • hATTR
  • Neuromuscular Diseases
  • COVID-19
  • Other
Companies covered
  • Sobi
  • Novartis
  • Pfizer
  • Biogen
  • Sylentis
  • Silence Therapeutics
  • Secarna
  • Sarepta Therapeutics
  • Regulus Therapeutics
  • ProQR
  • Nippon Shinyaku
  • Moderna Therapeutics
  • MiNA Therapeutics
  • Jazz Pharmaceuticals
  • Ionis Pharmaceuticals
  • Dicerna
  • CureVac
  • BioNTech
  • Arrowhead
  • Alnylam

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.3 Global Oligonucleotide Therapy-based Drug Market Size Overview by Region 2021 VS 2025 VS 2032
  4. 1.4 Global Oligonucleotide Therapy-based Drug Market Size by Region (2021-2032)
  5. 1.4.1 Global Oligonucleotide Therapy-based Drug Market Size by Region (2021-2026)
  6. 1.4.2 Global Oligonucleotide Therapy-based Drug Market Size by Region (2027-2032)
  7. 1.5 Key Regions Oligonucleotide Therapy-based Drug Market Size (2021-2032)
  8. 1.5.1 North America Oligonucleotide Therapy-based Drug Market Size Growth Rate (2021-2032)
  9. 1.5.2 Europe Oligonucleotide Therapy-based Drug Market Size Growth Rate (2021-2032)
  10. 1.5.3 Asia-Pacific Oligonucleotide Therapy-based Drug Market Size Growth Rate (2021-2032)
  11. 1.5.4 South America Oligonucleotide Therapy-based Drug Market Size Growth Rate (2021-2032)
  12. 1.5.5 Middle East & Africa Oligonucleotide Therapy-based Drug Market Size Growth Rate (2021-2032)
2 Oligonucleotide Therapy-based Drug Market by Type
  1. 2.1 Type Introduction
  2. 2.1.1 mRNA
  3. 2.1.2 siRNA
  4. 2.1.3 Antisense Oligonucleotides (ASO)
  5. 2.2 Global Oligonucleotide Therapy-based Drug Market Size by Type
  6. 2.2.1 Global Oligonucleotide Therapy-based Drug Market Size Overview by Type (2021-2032)
  7. 2.2.2 Global Oligonucleotide Therapy-based Drug Historic Market Size Review by Type (2021-2026)
  8. 2.2.3 Global Oligonucleotide Therapy-based Drug Market Size Forecasted by Type (2027-2032)
  9. 2.3 Global Oligonucleotide Therapy-based Drug Market Size by Regions
  10. 2.3.1 North America Oligonucleotide Therapy-based Drug Market Size Breakdown by Type (2021-2026)
  11. 2.3.2 Europe Oligonucleotide Therapy-based Drug Market Size Breakdown by Type (2021-2026)
  12. 2.3.3 Asia-Pacific Oligonucleotide Therapy-based Drug Market Size Breakdown by Type (2021-2026)
  13. 2.3.4 South America Oligonucleotide Therapy-based Drug Market Size Breakdown by Type (2021-2026)
  14. 2.3.5 Middle East and Africa Oligonucleotide Therapy-based Drug Market Size Breakdown by Type (2021-2026)
3 Oligonucleotide Therapy-based Drug Market by Application
  1. 3.1 Type Introduction
  2. 3.1.1 hATTR
  3. 3.1.2 Neuromuscular Diseases
  4. 3.1.3 COVID-19
  5. 3.1.4 Other
  6. 3.2 Global Oligonucleotide Therapy-based Drug Market Size by Application
  7. 3.2.1 Global Oligonucleotide Therapy-based Drug Market Size Overview by Application (2021-2032)
  8. 3.2.2 Global Oligonucleotide Therapy-based Drug Historic Market Size Review by Application (2021-2026)
  9. 3.2.3 Global Oligonucleotide Therapy-based Drug Market Size Forecasted by Application (2027-2032)
  10. 3.3 Global Oligonucleotide Therapy-based Drug Market Size by Regions
  11. 3.3.1 North America Oligonucleotide Therapy-based Drug Market Size Breakdown by Application (2021-2026)
  12. 3.3.2 Europe Oligonucleotide Therapy-based Drug Market Size Breakdown by Application (2021-2026)
  13. 3.3.3 Asia-Pacific Oligonucleotide Therapy-based Drug Market Size Breakdown by Application (2021-2026)
  14. 3.3.4 South America Oligonucleotide Therapy-based Drug Market Size Breakdown by Application (2021-2026)
  15. 3.3.5 Middle East and Africa Oligonucleotide Therapy-based Drug Market Size Breakdown by Application (2021-2026)
4 Global Market Dynamics
  1. 4.1 Oligonucleotide Therapy-based Drug Industry Trends
  2. 4.2 Oligonucleotide Therapy-based Drug Industry Drivers
  3. 4.3 Oligonucleotide Therapy-based Drug Industry Opportunities and Challenges
  4. 4.4 Oligonucleotide Therapy-based Drug Industry Restraints
5 Competitive Insights by Company
  1. 5.1 Global Top Players by Oligonucleotide Therapy-based Drug Revenue (2021-2026)
  2. 5.2 Global Oligonucleotide Therapy-based Drug Industry Company Ranking, 2024 VS 2025 VS 2026
  3. 5.3 Global Oligonucleotide Therapy-based Drug Key Company Headquarters & Area Served
  4. 5.4 Global Oligonucleotide Therapy-based Drug Company, Product Type & Application
  5. 5.5 Global Oligonucleotide Therapy-based Drug Company Commercialization Time
  6. 5.6 Market Competitive Analysis
  7. 5.6.1 Global Oligonucleotide Therapy-based Drug Market CR5 and HHI
  8. 5.6.2 Global Top 5 and 10 Oligonucleotide Therapy-based Drug Players Market Share by Revenue in 2025
  9. 5.6.3 2025 Oligonucleotide Therapy-based Drug Tier 1, Tier 2, and Tier 3
6 Company Profiles
  1. 6.1 Sobi
  2. 6.1.1 Sobi Company Information
  3. 6.1.2 Sobi Business Overview
  4. 6.1.3 Sobi Oligonucleotide Therapy-based Drug Revenue, Global Share and Gross Margin (2021-2026)
  5. 6.1.4 Sobi Oligonucleotide Therapy-based Drug Product Portfolio
  6. 6.1.5 Sobi Recent Developments
  7. 6.2 Novartis
  8. 6.2.1 Novartis Company Information
  9. 6.2.2 Novartis Business Overview
  10. 6.2.3 Novartis Oligonucleotide Therapy-based Drug Revenue, Global Share and Gross Margin (2021-2026)
  11. 6.2.4 Novartis Oligonucleotide Therapy-based Drug Product Portfolio
  12. 6.2.5 Novartis Recent Developments
  13. 6.3 Pfizer
  14. 6.3.1 Pfizer Company Information
  15. 6.3.2 Pfizer Business Overview
  16. 6.3.3 Pfizer Oligonucleotide Therapy-based Drug Revenue, Global Share and Gross Margin (2021-2026)
  17. 6.3.4 Pfizer Oligonucleotide Therapy-based Drug Product Portfolio
  18. 6.3.5 Pfizer Recent Developments
  19. 6.4 Biogen
  20. 6.4.1 Biogen Company Information
  21. 6.4.2 Biogen Business Overview
  22. 6.4.3 Biogen Oligonucleotide Therapy-based Drug Revenue, Global Share and Gross Margin (2021-2026)
  23. 6.4.4 Biogen Oligonucleotide Therapy-based Drug Product Portfolio
  24. 6.4.5 Biogen Recent Developments
  25. 6.5 Sylentis
  26. 6.5.1 Sylentis Company Information
  27. 6.5.2 Sylentis Business Overview
  28. 6.5.3 Sylentis Oligonucleotide Therapy-based Drug Revenue, Global Share and Gross Margin (2021-2026)
  29. 6.5.4 Sylentis Oligonucleotide Therapy-based Drug Product Portfolio
  30. 6.5.5 Sylentis Recent Developments
  31. 6.6 Silence Therapeutics
  32. 6.6.1 Silence Therapeutics Company Information
  33. 6.6.2 Silence Therapeutics Business Overview
  34. 6.6.3 Silence Therapeutics Oligonucleotide Therapy-based Drug Revenue, Global Share and Gross Margin (2021-2026)
  35. 6.6.4 Silence Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
  36. 6.6.5 Silence Therapeutics Recent Developments
  37. 6.7 Secarna
  38. 6.7.1 Secarna Company Information
  39. 6.7.2 Secarna Business Overview
  40. 6.7.3 Secarna Oligonucleotide Therapy-based Drug Revenue, Global Share and Gross Margin (2021-2026)
  41. 6.7.4 Secarna Oligonucleotide Therapy-based Drug Product Portfolio
  42. 6.7.5 Secarna Recent Developments
  43. 6.8 Sarepta Therapeutics
  44. 6.8.1 Sarepta Therapeutics Company Information
  45. 6.8.2 Sarepta Therapeutics Business Overview
  46. 6.8.3 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Revenue, Global Share and Gross Margin (2021-2026)
  47. 6.8.4 Sarepta Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
  48. 6.8.5 Sarepta Therapeutics Recent Developments
  49. 6.9 Regulus Therapeutics
  50. 6.9.1 Regulus Therapeutics Company Information
  51. 6.9.2 Regulus Therapeutics Business Overview
  52. 6.9.3 Regulus Therapeutics Oligonucleotide Therapy-based Drug Revenue, Global Share and Gross Margin (2021-2026)
  53. 6.9.4 Regulus Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
  54. 6.9.5 Regulus Therapeutics Recent Developments
  55. 6.10 ProQR
  56. 6.10.1 ProQR Company Information
  57. 6.10.2 ProQR Business Overview
  58. 6.10.3 ProQR Oligonucleotide Therapy-based Drug Revenue, Global Share and Gross Margin (2021-2026)
  59. 6.10.4 ProQR Oligonucleotide Therapy-based Drug Product Portfolio
  60. 6.10.5 ProQR Recent Developments
  61. 6.11 Nippon Shinyaku
  62. 6.11.1 Nippon Shinyaku Company Information
  63. 6.11.2 Nippon Shinyaku Business Overview
  64. 6.11.3 Nippon Shinyaku Oligonucleotide Therapy-based Drug Revenue, Global Share and Gross Margin (2021-2026)
  65. 6.11.4 Nippon Shinyaku Oligonucleotide Therapy-based Drug Product Portfolio
  66. 6.11.5 Nippon Shinyaku Recent Developments
  67. 6.12 Moderna Therapeutics
  68. 6.12.1 Moderna Therapeutics Company Information
  69. 6.12.2 Moderna Therapeutics Business Overview
  70. 6.12.3 Moderna Therapeutics Oligonucleotide Therapy-based Drug Revenue, Global Share and Gross Margin (2021-2026)
  71. 6.12.4 Moderna Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
  72. 6.12.5 Moderna Therapeutics Recent Developments
  73. 6.13 MiNA Therapeutics
  74. 6.13.1 MiNA Therapeutics Company Information
  75. 6.13.2 MiNA Therapeutics Business Overview
  76. 6.13.3 MiNA Therapeutics Oligonucleotide Therapy-based Drug Revenue, Global Share and Gross Margin (2021-2026)
  77. 6.13.4 MiNA Therapeutics Oligonucleotide Therapy-based Drug Product Portfolio
  78. 6.13.5 MiNA Therapeutics Recent Developments
  79. 6.14 Jazz Pharmaceuticals
  80. 6.14.1 Jazz Pharmaceuticals Company Information
  81. 6.14.2 Jazz Pharmaceuticals Business Overview
  82. 6.14.3 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue, Global Share and Gross Margin (2021-2026)
  83. 6.14.4 Jazz Pharmaceuticals Oligonucleotide Therapy-based Drug Product Portfolio
  84. 6.14.5 Jazz Pharmaceuticals Recent Developments
  85. 6.15 Ionis Pharmaceuticals
  86. 6.15.1 Ionis Pharmaceuticals Company Information
  87. 6.15.2 Ionis Pharmaceuticals Business Overview
  88. 6.15.3 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Revenue, Global Share and Gross Margin (2021-2026)
  89. 6.15.4 Ionis Pharmaceuticals Oligonucleotide Therapy-based Drug Product Portfolio
  90. 6.15.5 Ionis Pharmaceuticals Recent Developments
  91. 6.16 Dicerna
  92. 6.16.1 Dicerna Company Information
  93. 6.16.2 Dicerna Business Overview
  94. 6.16.3 Dicerna Oligonucleotide Therapy-based Drug Revenue, Global Share and Gross Margin (2021-2026)
  95. 6.16.4 Dicerna Oligonucleotide Therapy-based Drug Product Portfolio
  96. 6.16.5 Dicerna Recent Developments
  97. 6.17 CureVac
  98. 6.17.1 CureVac Company Information
  99. 6.17.2 CureVac Business Overview
  100. 6.17.3 CureVac Oligonucleotide Therapy-based Drug Revenue, Global Share and Gross Margin (2021-2026)
  101. 6.17.4 CureVac Oligonucleotide Therapy-based Drug Product Portfolio
  102. 6.17.5 CureVac Recent Developments
  103. 6.18 BioNTech
  104. 6.18.1 BioNTech Company Information
  105. 6.18.2 BioNTech Business Overview
  106. 6.18.3 BioNTech Oligonucleotide Therapy-based Drug Revenue, Global Share and Gross Margin (2021-2026)
  107. 6.18.4 BioNTech Oligonucleotide Therapy-based Drug Product Portfolio
  108. 6.18.5 BioNTech Recent Developments
  109. 6.19 Arrowhead
  110. 6.19.1 Arrowhead Company Information
  111. 6.19.2 Arrowhead Business Overview
  112. 6.19.3 Arrowhead Oligonucleotide Therapy-based Drug Revenue, Global Share and Gross Margin (2021-2026)
  113. 6.19.4 Arrowhead Oligonucleotide Therapy-based Drug Product Portfolio
  114. 6.19.5 Arrowhead Recent Developments
  115. 6.20 Alnylam
  116. 6.20.1 Alnylam Company Information
  117. 6.20.2 Alnylam Business Overview
  118. 6.20.3 Alnylam Oligonucleotide Therapy-based Drug Revenue, Global Share and Gross Margin (2021-2026)
  119. 6.20.4 Alnylam Oligonucleotide Therapy-based Drug Product Portfolio
  120. 6.20.5 Alnylam Recent Developments
7 North America
  1. 7.1 North America Oligonucleotide Therapy-based Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 7.2 North America Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026)
  3. 7.3 North America Oligonucleotide Therapy-based Drug Market Size Forecast by Country (2027-2032)
8 Europe
  1. 8.1 Europe Oligonucleotide Therapy-based Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 8.2 Europe Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026)
  3. 8.3 Europe Oligonucleotide Therapy-based Drug Market Size Forecast by Country (2027-2032)
9 Asia-Pacific
  1. 9.1 Asia-Pacific Oligonucleotide Therapy-based Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 9.2 Asia-Pacific Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026)
  3. 9.3 Asia-Pacific Oligonucleotide Therapy-based Drug Market Size Forecast by Country (2027-2032)
10 South America
  1. 10.1 South America Oligonucleotide Therapy-based Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 10.2 South America Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026)
  3. 10.3 South America Oligonucleotide Therapy-based Drug Market Size Forecast by Country (2027-2032)
11 Middle East & Africa
  1. 11.1 Middle East & Africa Oligonucleotide Therapy-based Drug Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  2. 11.2 Middle East & Africa Oligonucleotide Therapy-based Drug Market Size by Country (2021-2026)
  3. 11.3 Middle East & Africa Oligonucleotide Therapy-based Drug Market Size Forecast by Country (2027-2032)
12 Concluding Insights
    13 Appendix
    1. 13.1 Reasons for Doing This Study
    2. 13.2 Research Methodology
    3. 13.3 Research Process
    4. 13.4 Authors List of This Report
    5. 13.5 Data Source
    6. 13.5.1 Secondary Sources
    7. 13.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst